Reven Holdings announces first patient dosed in clinical trial evaluating RJX for high-risk COVID-19
WESTMINSTER -- Reven Holdings, Inc. today announced the first patient has been dosed in the Phase I/II trial of RJX in high-risk COVID-19 patients ( ClinicalTrials.gov Identifier: NCT04708340; ... Read More
Thursday April 29, 2021
Flagship Biosciences and Leap Therapeutics announce partnership and approach using RNAscope and Image Analysis for patient enrollment
WESTMINSTER and CAMBRIDGE, Mass. -- Flagship Biosciences , a leader in data-centric pathology and tissue analysis, and Massachusetts-based Leap Therapeutics (Nasdaq: LPTX), a biotechnology... Read More
Wednesday April 14, 2021
Maxar delivers spacecraft bus for NASA’s Psyche Mission to explore asteroid
WESTMINSTER -- Maxar Technologies (NYSE:MAXR) (TSX:MAXR) announced the delivery of the Solar Electric Propulsion (SEP) Chassis to NASA’s Jet Propulsion Laboratory (JPL) for the NASA Discovery... Read More
Tuesday March 30, 2021
Maxar awarded contract to support GEOINT exploitation for U.S. Army and combatant commands
WESTMINSTER -- Maxar Technologies (NYSE:MAXR) (TSX:MAXR) today announced it was awarded a U.S. Army contract worth as much as $48.3 million for support services in geospatial intelligence (GEOINT).... Read More
Monday March 29, 2021
Flagship Biosciences announces new patent
WESTMINSTER -- Flagship Biosciences announced the United States Patent and Trademark Office has issued the company a new patent, No. 10,839,512, entitled “ Method of dot detection within images... Read More
Thursday February 18, 2021
Maxar Technologies appoints Heather Wilson to board of directors
WESTMINSTER -- Maxar Technologies (NYSE:MAXR) (TSX:MAXR) today announced the appointment of Dr. Heather Wilson to serve on the company’s board of directors. Wilson will serve as a director... Read More
Tuesday January 19, 2021
Cerapedics announces commercial launch of i-FACTOR®+ Matrix in Canada for surgeries
WESTMINSTER -- Cerapedics announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada. "We are excited to announce that i-FACTOR+ Matrix is now fully... Read More
Friday November 6, 2020
TriSalus Life Sciences lays out therapeutic strategy upon acquisition of first therapeutic candidate
DENVER and CHICAGO -- TriSalus Life Sciences (TriSalus), an emerging immune-oncology company committed to transforming outcomes for patients with solid tumors, announced its therapeutic clinical... Read More
Monday September 28, 2020
IN Sponsors
Browse
Entrepreneurial by Nature
